SANTEN PHARMACEUTICAL

Terms

• Consolidated: the parent company together with the subsidiaries it consolidates
• Parent-only: the single company that filed the annual securities report
• Calculated: a disclosed figure put through the formula shown
• Not disclosed: no such value in the filing (not treated as zero)
• Not retrieved: a value this page could not extract, including values in the filing that could not be matched. The same item may appear in another table
• Segment: a business division the company uses in its disclosures
• Industry median: the middle value among companies in the same industry that disclose the item
• ★: position when every company is lined up by value (not a judgement of the company)See the formulas
• Source: document name, period covered, filing date and where it was obtained
• Tables scroll sideways

Key figures

• Operating margin 16.4%　Operating income ÷ net sales 　＝ ¥47.8 billion ÷ ¥291.6 billion
  Operating income ÷ net sales. The denominator is Net sales (Consolidated, IFRS).
• Net margin 12.8%　Net income ÷ net sales 　＝ ¥37.4 billion ÷ ¥291.6 billion
  Net income ÷ net sales. The denominator is Net sales (Consolidated, IFRS).
• Sales per employee 73,493,952 yen　Sales or operating revenue ÷ employees 　＝ ¥291.6 billion ÷ 3,968 people
  Sales or operating revenue ÷ employees. The denominator is Number of employees (Consolidated, Japanese GAAP).
• Total asset turnover 0.69 times　Sales or operating revenue ÷ total assets 　＝ ¥291.6 billion ÷ ¥423.0 billion
  Sales or operating revenue ÷ total assets. The denominator is Total assets (Consolidated, IFRS).
• Net assets to total assets 70%　Net assets ÷ total assets 　＝ ¥296.0 billion ÷ ¥423.0 billion
  Net assets ÷ total assets. The denominator is Total assets (Consolidated, IFRS).

Company details

• Representative　President, Representative Director, gBizINFO

Amounts by account

• Totals and their component lines together; consolidated and parent-only figures mixed (right-hand column)

Selling, general and administrative expenses

• Breakdown of selling, general and administrative expenses (costs of selling and running the company). Cost of sales not included
• Each item: already inside the SG&A total (not added to it)

Finance

• Net assets to total assets　Net assets ÷ total assets
• Return on assets (ROA)　Net income ÷ total assets (consolidated)
• Net assets per share　Parent only
• Free cash flow　Free cash flow: operating cash flow (cash generated by the business) plus investing cash flow (asset purchases, disposals and other investments), consolidated
• Total assets　Consolidated
• Goodwill (the part of the acquisition price above the net assets acquired)　3% of net assets (consolidated)

Capital allocation

• ★: position when all companies are sorted by value and cut into fifths (a position, not a rating). The five items with ★: only where both numerator and denominator are available on a consolidated basisSee the formulas
• Cash conversion　Net cash provided by (used in) operating activities ÷ operating income
• Increase in working capital　(increase in trade receivables + increase in inventories) ÷ net sales (or operating revenue)。Trade receivables down ¥2.7 billion + inventories up ¥10.0 billion, over net sales ¥291.6 billion
• Property, plant and equipment purchases relative to depreciation　Purchase of property, plant and equipment ÷ depreciation。Purchase of property, plant and equipment ¥6.8 billion, over depreciation ¥18.4 billion
• Return to shareholders　(dividends paid + purchase of treasury stock) ÷ net cash provided by operating activities。Dividends paid ¥12.6 billion + purchase of treasury stock ¥32.8 billion, over operating cash flow ¥43.5 billion

Long-term changes in performance

• Revenue　Disclosed value for 2026 ÷ disclosed value for 2013

Year-on-year comparison

• Year on year: calculated only where the item, reporting range and accounting standard match and the periods are consecutive
• Comparison basis not confirmed: periods with a change of accounting standard or reporting range, a moved fiscal year end, or an unconfirmed period
• ◆: a period where revenue moved 20% or more from the prior year, profit as a share of revenue moved 2.0 percentage points or more, or profit or loss changed sign. Item used named in the table and list. Not a ranking of companies

Earnings and net assets per share over time

• Earnings per share = net profit ÷ shares; net assets per share = net assets ÷ shares. Disclosed values from the key financial indicators of the annual securities report. No share prices used

Dividend history

• Payout ratio: dividends as a proportion of net profit. Dividend amounts and payout ratios: the reporting company’s parent-only disclosed values (as written in the annual securities report, not recalculated from consolidated profit). Consecutive increases: years in a row, from the latest backwards, in which the annual dividend per share rose. Consecutive years with a dividend: years in a row with an annual dividend per share above zero. Both this site’s own count (not the criteria of any published index). A year with no disclosure not read as zero; counting stops there. Range limited to the years listed above. Flagged 1 years: a note about a stock split or share consolidation, or a period other than 12 months. No calculation across those years, as the dividend per share may rest on a different share base.

Share ownership by holder category

• Source: ownership table, annual securities report. Percentages as disclosed, calculated on trading units (some companies do not total exactly 100%). Foreign holders (total): institutions and individuals combined. “Individuals and others”: a register category (not necessarily the share actually held by individuals). Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

Major shareholders

• Source: major shareholders table, annual securities report. Trust bank holdings as written (whose trust is not disclosed)

Research and development expenses and capital expenditure

• Research and development: total in the R&D section of the annual securities report. Capital expenditure: this year’s actual spending in the capital expenditure overview (not a plan). Years: only those available in the annual securities reports on hand (one to four per company); no row for other years. Share of revenue: divided by consolidated revenue in the same annual securities report. Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

Revenue scale in the same industry

• Revenue (disclosed values) of companies in the same industry, using the same grouping as the industry pages. Only the top three and the two companies either side of this one. Bar length relative to the largest company (100). An order of size, not a ranking of quality

Workforce information

• All four: the reporting company (parent-only), as disclosed in the employee section of the annual securities report. Employees across the consolidated group: 3,968 (a different scope, kept apart from the four above). Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

People and organisation

• Sales per employee　Net sales (or operating revenue) ÷ employees
• Operating income per employee　Operating income ÷ employees
• Wage gap between men and women　Women's pay with men's pay set to 100, reporting company
• Women in managerial positions　Reporting company (parent only)
• Share of female employees　gBizINFO, covering 正社員
• Men taking childcare leave　Reporting company (parent only)
• Average length of service by gender　gBizINFO, covering 正社員
• Employees by gender　gBizINFO

Workplace information filings

• Source: processed from Shokuba-labo, the workplace information site of the Ministry of Health, Labour and Welfare. Items the company filed only Shokuba-labo

Greenhouse gas emissions

• Source: processed from the Ministry of the Environment’s greenhouse gas calculation, reporting and disclosure system (EEGS). Companies required to report only Ministry of the Environment (EEGS)

Audit and disclosure information

• Whether there is a going concern note (the accounting assumption that a company will continue operating), and audit information
• Audit firm, audit fees, going concern note and accounting standard: facts written in the latest annual securities report and the audit report filed with it (not a judgement of the company). Going concern note: “note” when the note text is present, “not applicable” when the report states nothing to report, “cannot be determined” when neither appears. Note text not reproduced. Amended filings not shown (annual securities reports only)

Data sources and calculation methods

Primary source: the annual securities report of SANTEN PHARMACEUTICAL CO.,LTD. on EDINET, the FSA’s disclosure system (free to read)
Corporate number: 5120001051819 / Accounting standard: IFRS

• Amounts: machine transcription of EDINET XBRL (no manual re-keying). Long narrative notes are text and not in the account list. Identifiers: machine transcription of the EDINET code list (retrieved 2026-08-22)
• ★: position of the value calculated from disclosed figures among the 4,240 companies on this site, on a five-step scale. Not a judgement of the company. No forecasts usedThe formulas and how they are counted
• No rank: net assets as a share of total assets, cash conversion and revenue per employee (size alone does not show quality). Industry median shown for comparison. Cash conversion of 100%: operating cash flow equal to operating profit
• Profit-and-loss chart: only where “sales − cost of sales − SG&A = operating income” holds between disclosed values. Cost breakdown: the six largest SG&A items
• Trend charts: key financial indicators of the annual securities report. Amounts in billions of yen (dividend per share in yen). Long-run chart joins reports filed in different years (newer report for overlapping years). Some items stop part-way after a change of accounting standard. A stock split changes the weight of one share. Consolidated and parent-only in separate tables
• Revenue scale in the same industry: bars of revenue (disclosed values) of companies in the same industry grouping as the industry pages, largest first. Only the top three and the two companies either side of this one. Each company’s latest fiscal year. An order of size, not a ranking of quality or an investment view
• Share prices: not published (no data source allows redistribution). No share-price-based indicators (such as the price earnings ratio) and no extension of past growth into the future
• Average age, average length of service and average annual salary: the reporting company alone (the parent). At a holding company, a small head-office staff. Payout ratio (basic facts): dividend per share ÷ consolidated earnings per share, calculated here (the payout ratio in the annual securities report is the reporting company’s figure, on a different basis). Representative and founding date: gBizINFO (Ministry of Economy, Trade and Industry), some companies only
• “Retrieved disclosed figures”: every value readable as a number from the annual securities report. Company-wide values only (no segment or other breakdowns)
• Segment table: machine transcription of the segment information in the annual securities report. Business names as labelled by the company in its XBRL. No table where segment sales differ from the disclosed total by more than 1%. Adjustments, corporate, eliminations and “other” left out of the table and the share denominator, as they are not businesses
• Breakdowns of amounts, not diagrams of how the business works. Who pays whom, and for what, is not in the disclosed figures; no lines drawn from guesswork